No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa

Lisette M. Prens; Christine B. Ardon; Kelsey R. van Straalen; Hessel H. van der Zee; Marc A.J. Seelen; Jon D. Laman; Errol P. Prens; Barbara Horváth; Jeffrey Damman

doi:10.1016/j.jid.2021.03.037

No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa

Lisette M. Prens^*, Christine B. Ardon, Kelsey R. van Straalen, Hessel H. van der Zee, Marc A.J. Seelen, Jon D. Laman, Errol P. Prens, Barbara Horváth, Jeffrey Damman

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

8 Citations (Scopus)

24 Downloads (Pure)

Original language	English
Pages (from-to)	2966-2969.e1
Journal	Journal of Investigative Dermatology
Volume	141
Issue number	12
Early online date	8 Jul 2021
DOIs	https://doi.org/10.1016/j.jid.2021.03.037
Publication status	Published - 1 Dec 2021

Bibliographical note

Funding Information:
The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337). Conceptualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Data Curation: LMP, CBA, KRVS, MAJS, EPP, JD; Formal Analysis: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, JD; Funding Acquisition: MAJS, EPP, BH, JD; Investigation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Methodology: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Project Administration: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Resources: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Supervision: MAJS, EPP, JD; Validation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Visualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Original Draft Preparation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Review and Editing: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD, AbbVie (Hoofddorp, The Netherlands) had no role in the design or conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication.

Funding Information:
The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337).

Access to Document

10.1016/j.jid.2021.03.037Licence: CC BY-NC-ND

No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis SuppurativaFinal published version, 521 KBLicence: CC BY-NC-ND

Cite this

@article{2497eff18b974a5ba0b15265701e8036,

title = "No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa",

author = "Prens, \{Lisette M.\} and Ardon, \{Christine B.\} and \{van Straalen\}, \{Kelsey R.\} and \{van der Zee\}, \{Hessel H.\} and Seelen, \{Marc A.J.\} and Laman, \{Jon D.\} and Prens, \{Errol P.\} and Barbara Horv{\'a}th and Jeffrey Damman",

note = "Funding Information: The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337). Conceptualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Data Curation: LMP, CBA, KRVS, MAJS, EPP, JD; Formal Analysis: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, JD; Funding Acquisition: MAJS, EPP, BH, JD; Investigation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Methodology: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Project Administration: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Resources: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Supervision: MAJS, EPP, JD; Validation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Visualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Original Draft Preparation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Review and Editing: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD, AbbVie (Hoofddorp, The Netherlands) had no role in the design or conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication. Funding Information: The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337). ",

year = "2021",

month = dec,

day = "1",

doi = "10.1016/j.jid.2021.03.037",

language = "English",

volume = "141",

pages = "2966--2969.e1",

journal = "Journal of Investigative Dermatology",

issn = "0022-202X",

publisher = "Elsevier",

number = "12",

}

TY - JOUR

T1 - No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa

AU - Prens, Lisette M.

AU - Ardon, Christine B.

AU - van Straalen, Kelsey R.

AU - van der Zee, Hessel H.

AU - Seelen, Marc A.J.

AU - Laman, Jon D.

AU - Prens, Errol P.

AU - Horváth, Barbara

AU - Damman, Jeffrey

N1 - Funding Information: The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337). Conceptualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Data Curation: LMP, CBA, KRVS, MAJS, EPP, JD; Formal Analysis: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, JD; Funding Acquisition: MAJS, EPP, BH, JD; Investigation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Methodology: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Project Administration: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Resources: LMP, CBA, KRVS, MAJS, EPP, BH, JD; Supervision: MAJS, EPP, JD; Validation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Visualization: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Original Draft Preparation: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD; Writing - Review and Editing: LMP, CBA, KRVS, HHVDZ, MAJS, JDL, EPP, BH, JD, AbbVie (Hoofddorp, The Netherlands) had no role in the design or conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication. Funding Information: The authors thank Anita Meter (University Medical Center Groningen, The Netherlands) for performing the complement measurements. We thank the patients with HS and the healthy volunteers for their participation. The HiScreen Registry and Biobank are financially supported by AbbVie (The Netherlands). The collection of blood and patient data used in this study was approved by the Institutional Review Board of the Erasmus University Medical Center (Rotterdam, The Netherlands) (MEC-2016-246/MEC-2013-337).

PY - 2021/12/1

Y1 - 2021/12/1

UR - http://www.scopus.com/inward/record.url?scp=85111796490&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2021.03.037

DO - 10.1016/j.jid.2021.03.037

M3 - Comment/Letter to the editor

C2 - 34252397

AN - SCOPUS:85111796490

SN - 0022-202X

VL - 141

SP - 2966-2969.e1

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 12

ER -

No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa

Bibliographical note

Access to Document

Other files and links

Cite this